Digipath
Home > Boards > US Listed > Medical - Equipment >

Neovasc, Inc. (NVCN)

NVCN RSS Feed
Add NVCN Price Alert      Hide Sticky   Hide Intro
Moderator: lister
Search This Board: 
Last Post: 1/23/2019 5:59:55 PM - Followers: 216 - Board type: Free - Posts Today: 0


Trading for
$0.061 as of Thurs. March 29th, 2018, well under two recent Price Targets of $2.00 and $0.50.
Increased chatter amongst investors of a Partnership or Buyout, see below. 


Latest Analyst Ratings:

March 29th, 2018 3:07 AM EDT
Neovasc Inc. PT updated to $2.00 at Leerink Partners, states that 'Tiara Clinical Trials Continue to Progress' Maintains 'Outperform' Rating.
https://www.streetinsider.com/Analyst+PT+Change/Neovasc+%28NVCN%29+PT+Lowered+to+%242+at+Leerink+Partners%3B+Tiara+Clinical+Trials+Continue+to+Progress/13997143.html

March 29th, 2018 
Canaccord Genuity Updates Neovasc Inc (US) (NVCN) Price Target to $0.50 and has a "Buy" rating.
https://registrarjournal.com/2018/03/29/canaccord-genuity-lowers-neovasc-inc-us-nvcn-price-target-to-0-50.html


Latest Earnings Report - March 28th, 2018
https://seekingalpha.com/article/4159758-neovascs-nvcn-ceo-fred-colen-q4-2017-results-earnings-call-transcript
EPS of $-0.28 misses by $-0.02 
Revenue of $5.39M (- 43.3% Y/Y) beats by $1.29M

Trader's takeaway from the latest Earnings Report: (Updated on April 1st, 2018)
1. No R/S mentioned, 2. Tiara Prescreen implementation in Europe soon (as early as this week), 3. Updates on Tiara / Reducer enrollments shown to have been very successful and increasing in size, 4. Cash to last through Q3 2018, 5. Revenues were down/but so were expenses.

Also on the conference call, they reported that the $112 M lawsuit has been fully paid and settled. Neovasc said that “there are no other monetary damages arising from the award,” and announced that it will remain the joint inventor of its ‘964 patent related to its Tiara transcatheter mitral valve replacement device. Neovasc will share the patent along with 2 employees of CardiAQ Valve, with both parties “having freedom to use the patent without an obligation to pay royalties to the other", according to a press release. Source: NeoVasc shares surge 45% on affirmed Tiara patent case decision against Edwards.  https://www.massdevice.com/neovasc-shares-surge-45-affirmed-tiara-patent-case-decision-edwards/

Possible Partnership in the works?
This was taken from the latest Earnings Conference call on March 28th, 2018 (link to entire transcript provided above, courtesy of SeekingAlpha.com)
Newly acquired CEO/President Fred Colen hints at being open to a partnership.  Have a look at what he says:
Possible partnership?

Possible Buy Out in the works? 
Check out newly acquired CEO Fred Colen's bio below (spoiler alert: he worked with $BSX for 8 years as CTO) and see how this all ties together. 

Don't Be Surprised if Boston Scientific (BSX) Buys Neovasc (NVCN)- JMP  



MARCH 30, 2018 Article:
http://www.editiontruth.com/heart-valve-devices-market-projected-grow-us-16-2-bn-end-2025/



Neovasc has a unique opportunity to take a share of that US$16.2 Billion with this patent along with many other patents that they own.
Patent # 
8,579,964  (Link to USPTO - UNITED STATES PATENT AND TRADEMARK OFFICE)
SOURCE:  http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,579,964.PN.&OS=PN/8,579,964&RS=PN/8,579,964

VERY IN DEPTH DD HERE - ANOTHER MUST READ HERE 
Neovasc's Tiara and other TMVR devices
https://docs.google.com/document/d/1OvI4lcwVL_NbcH9SIveG-sWiSWfTfRUZxlxEcUV_5RA/edit
______________________________________________________________________________________________________________________
______________________________________________________________________________________________________________________
{{{{{MAJOR UPDATE:ACQUISITION ALERT COLLABORATION WITH BOSTON SCIENTIFIC :Nasdaq"BSX" TAKING 15% OWNERSHIP STAKE IN: Nasdaq"NVCN" AND 
US$75 MILLION AGREEMENT 12/02/16}}}}
                                                        

Neovasc and Boston Scientific Reach US$75 Million Agreement 
12/2/2016 7:00:00 AM - PR Newswire 

 
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities 
12/2/2016 7:00:00 AM - PR Newswire 

NVCN + BSX = 15% stake = +350% for stock
                                                                                                       

 

Fred Colen - President and CEO
LOOK AT WHO WAS BROUGHT INTO AS CEO / PRESIDENT ON JANUARY 22nd 2018 AND THE CONNECTIONS WITH BOSTON SCIENTIFIC ($BSX)!!! 

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.  

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member." 

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years, including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry. 


Also note:
$BSX Boston Scientific laid off 300 employees just recently on March 27th, 2018
, perhaps to make room for the takeover of $NVCN ?? Who knows?? They already own 15% of NVCN.
source: https://www.massdevice.com/boston-scientific-lays-off-nearly-300-from-valencia-neuromod-facilities/ 

          
                                                                                          


                                                                      About Neovasc                                                                        

                                                     Neovasc Inc. is a specialty medical device company that develops, manufactures,
                                                     and markets products for the rapidly growing cardiovascular marketplace.

                                                                        Our products include the Tiara™ technology in development for the transcatheter
                                                                        treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of
                                                                        refractory angina.

                                                                         A Canadian Biotech company, headquartered in Vancouver, B.C. Canada, we are a
                                                                         publicly traded company, listed on NASDAQ: (NVCN) and the Toronto Stock
                                                                         Exchange TSX: (NVC) 


 

PRODUCTS

Tiara
Reducer

                                                    BUYOUT POTENTIAL                                        
              ------------------>>>>>>>>>>>>>Recent deals involving mitral valve companies<<<<<<<<<<<<<<--------------
"Great info and a MUST READ on the demand and for acquisitions for these type of companies here from last year this month now that remainder or any legal issues are getting ironed out through the final appeals days now , EVEN SHOWS THE $$ VALUES OF THE BOUGHT COMPANIES TOO:"
http://seekingalpha.com/article/3562756-boston-arrives-late-mitral-valve-party


""""UPDATE : NO INJUNCTION FOR TIARA DEVICE , CAN NOW MOVE FORWARD THUS MAKING IT MORE ATTRACTIVE FOR FUTURE BUYOUT"""""



Concensus Recommendation courtesy of NASDAQ.com 
Updated: April 1st, 2018:   STRONG BUY.
Source: https://www.nasdaq.com/symbol/nvcn/analyst-research


STRONG BUY                                  
Digipath
NVCN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVCN News: Report of Foreign Issuer (6-k) 01/23/2019 08:21:32 AM
NVCN News: Report of Foreign Issuer (6-k) 01/23/2019 08:21:04 AM
NVCN News: Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reduce... 01/23/2019 07:30:00 AM
NVCN News: Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reduce... 01/23/2019 07:30:00 AM
NVCN News: Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reduce... 01/23/2019 07:30:00 AM
News News Alert: Report of Foreign Issuer (6-k) 01/23/2019 08:21:32 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#11183   Nvcn is known for stealing others material. Just washington0000001 01/23/19 05:59:55 PM
#11182   I double my short.. Weee.. Crash coming.... Will PyschoNoobStock 01/23/19 11:42:00 AM
#11181   Push back over a $1 JJGl 01/23/19 08:33:49 AM
#11180   NEWS OUT https://neovasc.mediaroom.com/2019-01-23-Neovasc-announces-peer-review BenRN 01/23/19 07:38:19 AM
#11179   Why is no one thinking BSX wont buy simmons420 01/23/19 06:14:36 AM
#11178   * * $NVCN Video Chart 01-22-2019 * * ClayTrader 01/22/19 04:59:56 PM
#11177   yep...worth noting though, that Edwards paid Boston Scientific LutherTiggs 01/22/19 04:20:02 PM
#11176   The stock price problem lies with the last Never_Post 01/22/19 02:57:31 PM
#11175   News: $NVCN Neovasc Announces Dismissal of Claim brought whytestocks 01/22/19 02:06:16 PM
#11174   $25 buyout would be a pretty far stretch Snug Harbour 01/22/19 10:59:12 AM
#11173   200% to 250% profit from $0.70 (or $1.00 rrao11 01/22/19 10:56:22 AM
#11171   It will fade back down in coming days Snug Harbour 01/22/19 10:21:37 AM
#11170   got stopped out .875. quick $200 bucks Attila1905 01/22/19 10:16:56 AM
#11169   fade back to .70 cent range in coming days Snug Harbour 01/22/19 10:12:45 AM
#11168   in again .85 Attila1905 01/22/19 10:01:56 AM
#11167   Gap filled at .89 Never_Post 01/22/19 09:50:45 AM
#11166   Shorts got caught with pants down on that PR. DarkPool 01/22/19 09:39:31 AM
#11165   HELLO $DOLLARS$ Snug Harbour 01/22/19 09:07:15 AM
#11163   Yes! scotsand 01/22/19 08:09:38 AM
#11162   Boom and boooooooooom swing4thefences 01/22/19 07:41:27 AM
#11161   Clay just got played. Lol sorry for your losses Attila1905 01/22/19 07:37:23 AM
#11160   https://neovasc.mediaroom.com/2019-01-22-Neovasc-Announces-Dismissal-of-Claim-br BenRN 01/22/19 07:35:15 AM
#11159   * * $NVCN Video Chart 01-18-2019 * * ClayTrader 01/18/19 05:01:13 PM
#11158   Ramping up again swing4thefences 01/18/19 01:44:25 PM
#11157   sure, base of most companys lister 01/18/19 10:50:48 AM
#11156   Seems to be fizzling out here d-train 01/18/19 10:40:36 AM
#11155   Call it whatever you want but that's the Snug Harbour 01/18/19 10:34:43 AM
#11154   manipulation to keep this stock alive lister 01/18/19 10:31:34 AM
#11153   Agreed, holding for $1+ Might dip this morning though d-train 01/18/19 09:18:42 AM
#11152   It's going over a $1 to trade 10 Snug Harbour 01/17/19 09:15:56 PM
#11151   * * $NVCN Video Chart 01-17-2019 * * ClayTrader 01/17/19 05:35:14 PM
#11150   Stopped out .745 from .60 cents Attila1905 01/17/19 11:10:08 AM
#11149   Up and then right back down Joecanada13 01/17/19 11:06:00 AM
#11148   Got to love low float Nasdaq stocks when Snug Harbour 01/17/19 10:36:37 AM
#11147   .86 boooom Attila1905 01/17/19 10:23:24 AM
#11146   .86 and HEAVY volume. This is swing4thefences 01/17/19 10:23:07 AM
#11145   .77 strong day Attila1905 01/17/19 10:05:56 AM
#11144   Decent PM volume, let’s keep this breakout going. swing4thefences 01/17/19 09:13:03 AM
#11143   Looking at the L2.....not sure how that’s a Scotter17 01/16/19 07:54:32 PM
#11142   got lucky again at .60 Attila1905 01/16/19 07:20:30 PM
#11141   Nice after hour run! Broke through .70! BenRN 01/16/19 06:35:21 PM
#11140   ...well. Hows it going? Attila1905 01/16/19 03:35:46 PM
#11139   Here comes the ‘break-out upwards’! News? rrao11 01/16/19 03:29:59 PM
#11138   So far you are right, when there is Never_Post 01/16/19 02:05:35 PM
#11137   We need facts no rumor mill lister 01/16/19 01:02:45 PM
#11136   It’s time... Scotter17 01/16/19 12:19:49 PM
#11135   .65 told you guys yesterday. Its starting Attila1905 01/16/19 12:16:05 PM
#11134   .635 volume coming in. Watch out if .65 Attila1905 01/16/19 12:15:12 PM
#11133   I don't see a pop but a blubb lister 01/15/19 02:20:16 PM
#11131   Ill think of buying only if it goes Raj1989 01/15/19 01:41:09 PM
PostSubject